Breaking News

Financial Report: Baxter

July 17, 2014

Revenues up 16% in the quarter

Baxter
 
2Q Revenues: $4.3 billion (+16%)

2Q Earnings: $520 million (-12%)

YTD Revenues: $8.2 billion (+15%)

YTD Earnings: $1.1 billion (-6%)

Comments: BioScience revenues were up 7% to $1.8 billion in the quarter, led by double-digit growth of ADVATE and albumin, as well as increased global demand for GAMMAGARD LIQUID, biosurgery products and select vaccines. Medical Product sales were $2.5 billion, up 24%, driven primarily by strong sales of injectable drugs, anesthetics and nutritional therapies, as well as gains in peritoneal dialysis patients, particularly in the U.S. and emerging markets. Results include after-tax special items totaling $172 million, primarily for amortization and costs associated with revenue and product development milestones, remediation efforts for the in-progress SPECTRUM Infusion Pump recall, integration of Gambro AB, and Baxter’s planned separation into two independent healthcare companies.

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity